Secured Research | Equipment Finance Originator | Monitor | Monitor Suite | Converge | STRIPES Leadership
No Result
View All Result
ABF Journal
Forward for Specialty Finance
SUBSCRIBE
Lender & Services Directory
  • News
    • People
    • Economy
    • All News
  • Deals
  • Magazine
    • Magazine Issues
    • Nominations
  • Features
    • Articles & Insights
    • Resolving MCA Distress
    • Resolving Business Distress
  • Events
  • Recruiting
    • Molloy Associates Senior Asset Based Lending Originator Location: Remote
  • Advertise
    • Advertise for 2027
  • Contact Us
  • News
    • People
    • Economy
    • All News
  • Deals
  • Magazine
    • Magazine Issues
    • Nominations
  • Features
    • Articles & Insights
    • Resolving MCA Distress
    • Resolving Business Distress
  • Events
  • Recruiting
    • Molloy Associates Senior Asset Based Lending Originator Location: Remote
  • Advertise
    • Advertise for 2027
  • Contact Us
No Result
View All Result
ABF Journal
No Result
View All Result
Home Deal Announcements

Oaktree Capital Management Provides $30MM in Funding to Marinus Pharmaceuticals

byIan Koplin
April 1, 2022
in Deal Announcements

Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, received $30 million in funding under its existing credit agreement with Oaktree Capital Management. This additional funding became available as a result of the U.S. Food and Drug Administration’s (FDA) recent approval of the company’s new drug application (NDA) for ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older.

In May 2021, Marinus signed a credit financing agreement with Oaktree. Together with this $30 million drawdown, Marinus has drawn a total of $75 million in funding, including $15 million at signing of the credit financing agreement and $30 million upon the FDA’s acceptance of the CDD NDA filing in September 2021.

In addition, Marinus entered into an amendment to its previously disclosed agreement with the Biomedical Advanced Research and Development Authority (BARDA) to extend Marinus’ performance period for funding through the end of 2023 to align with updated timeline expectations for the Phase 3 RAISE trial in refractory status epilepticus (RSE). The base contract provides up to $21 million of research funding from BARDA for the ongoing RAISE trial, with potential for total BARDA research funding of up to $51 million based on success-based milestones.

Previous Post

First Eagle Investments to Acquire Napier Park Global Capital

Next Post

WSFS Bank Names Brickley SVP, Chief Credit Officer

Related Posts

Advanced Power Closes $100M Corporate Credit Facility
Deal Announcements

Akebia Enters Up to $140MM Term Loan Facility with Symbiotic Capital

November 17, 2026
Deal Announcements

Rowan Digital Infrastructure Secures $1.5B in New Capital from Apterra and Citi

November 17, 2026
Deal Announcements

Monroe Capital Supports OceanSound Partners’ Investment in IMSAR

November 17, 2026
Deal Announcements

SouthStar Capital Provides $750K Accounts Receivable Facility to Utah Landscaping Contractor

November 16, 2026
Deal Announcements

Countify Capital Provides $1MM Factoring Facility to Drive Staffing Company Growth

November 16, 2026
Deal Announcements

Assembled Brands Delivers $12.5MM Revolving Credit Facility to Sports Nutrition and Energy Drink Company

November 16, 2026
Next Post

WSFS Bank Names Brickley SVP, Chief Credit Officer

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About Us

For over 50 years, RAM Holdings’ brands have led the commercial finance industry in publishing, talent development, research and events. ABF Journal’s audience is comprised of as many as 18,000 specialty finance industry executives, private equity investors, investment bankers, advisors, service providers and more.

Our Brands

  • Secured Research
  • Equipment Finance Originator
  • Monitor
  • Monitor Suite
  • Converge
  • STRIPES Leadership

 

Learn More

  • Advertise
  • Magazine
  • Contact Us

Newsletter

Driving specialty finance forward for decades with insights, recognition and deals. Sign up now.

SUBSCRIBE >>

© 2025 RAM Group Holdings - A Leading Commercial Finance Publishing Group For Over 50 Years

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • News
    • People
    • Economy
    • All News
  • Deals
  • Features
    • Articles & Insights
    • Resolving MCA Distress
    • Resolving Business Distress
  • Magazine
    • Magazine Issues
    • Nominations
  • Molloy Associates
    • Molloy Associates Senior Asset Based Lending Originator Location: Remote
  • Events
  • Advertise
  • Contact Us
Provider Directory >>

© 2025 RAM Group Holdings - A Leading Commercial Finance Publishing Group For Over 50 Years